These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 12868552)

  • 1. Ticarcillin-clavulanic acid plus amikacin versus ceftazidime plus amikacin in the empirical treatment of fever in acute leukemia: a prospective randomized trial.
    Fanci R; Paci C; Leoni F; Casini C; Longo G
    J Chemother; 2003 Jun; 15(3):253-9. PubMed ID: 12868552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of ticarcillin/clavulanic acid versus ceftriaxone plus amikacin for fever and neutropenia in pediatric patients with leukemia and lymphoma.
    Petrilli AS; Cypriano M; Dantas LS; Lee LM; Vercillo Luisi MF; Torres B Silva KV; Pires Pereira CA
    Braz J Infect Dis; 2003 Apr; 7(2):111-20. PubMed ID: 12959681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of fever in neutropenic patients with acute leukemia: current role of ceftazidime plus amikacin as empiric therapy.
    Fanci R; Paci C; Martinez RL; Fabbri A; Pecile P; Leoni F; Longo G
    J Chemother; 2000 Jun; 12(3):232-9. PubMed ID: 10877519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients.
    Hess U; Böhme C; Rey K; Senn HJ
    Support Care Cancer; 1998 Jul; 6(4):402-9. PubMed ID: 9695210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer.
    Shenep JL; Hughes WT; Roberson PK; Blankenship KR; Baker DK; Meyer WH; Gigliotti F; Sixbey JW; Santana VM; Feldman S
    N Engl J Med; 1988 Oct; 319(16):1053-8. PubMed ID: 3050517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empirical therapy for neutropenic fever in children with malignancy.
    Hung KC; Chiu HH; Tseng YC; Wang JH; Lin HC; Tsai FJ; Peng CT
    J Microbiol Immunol Infect; 2003 Dec; 36(4):254-9. PubMed ID: 14723254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children.
    Aksoylar S; Cetingül N; Kantar M; Karapinar D; Kavakli K; Kansoy S
    Pediatr Hematol Oncol; 2004 Mar; 21(2):115-23. PubMed ID: 15160510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open evaluation of triple antibiotic therapy including vancomycin for febrile bone marrow transplant recipients with severe neutropenia.
    Bosi A; Laszlo D; Bacci S; Fanci R; Guidi S; Saccardi R; Vannucchi AM; Rossi-Ferrini P
    J Chemother; 1999 Aug; 11(4):287-92. PubMed ID: 10465131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of febrile episodes in neutropenic leukemic patients with the antibiotic combinations piperacillin or ceftazidime plus amikacin: results of a randomized study.
    Fenu S; Raccah R; Santilli S; Micozzi A; Girmena C; Martino P; Avvisati G
    Chemioterapia; 1988 Oct; 7(5):323-6. PubMed ID: 3066517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients.
    Metallidis S; Kollaras P; Giannakakis T; Seitanidis B; Kordosis T; Nikolaidis J; Hatzitolios A; Nikolaidis P
    Eur J Intern Med; 2008 Dec; 19(8):619-24. PubMed ID: 19046729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meropenem versus ceftazidime plus amikacin in the treatment of febrile episodes in neutropenic patients: a randomized study.
    de la Cámara R; Figuera A; Sureda A; Hermida G; Verge G; Olalla I; Fernández Rañada JM; Domingo Albos A
    Haematologica; 1997; 82(6):668-75. PubMed ID: 9580087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trimethoprim-sulfamethoxazole plus amikacin versus ceftazidime monotherapy as empirical treatment in patients with neutropenia and fever.
    Engervall P; Günther G; Ljungman P; Lönnqvist B; Hast R; Stiernstedt G; Kalin M; Ringertz S; Bjökholm M
    Scand J Infect Dis; 1996; 28(3):297-303. PubMed ID: 8863366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies.
    Cherif H; Björkholm M; Engervall P; Johansson P; Ljungman P; Hast R; Kalin M
    Scand J Infect Dis; 2004; 36(8):593-600. PubMed ID: 15370671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomised trial of empirical antibiotic therapy in febrile neutropenic patients with hematological disorders: ceftazidime versus azlocillin plus amikacin.
    Gibson J; Date L; Joshua DE; Young GA; Wilson A; Benn R; Benson W; Iland H; Vincent PC; Kronenberg H
    Aust N Z J Med; 1989 Oct; 19(5):417-25. PubMed ID: 2686610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial.
    Hidalgo M; Hornedo J; Lumbreras C; Trigo JM; Colomer R; Perea S; Gómez C; Ruiz A; García-Carbonero R; Cortés-Funes H
    Cancer; 1999 Jan; 85(1):213-9. PubMed ID: 9921995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of cefepime + netilmicin or ceftazidime + amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey.
    Agaoglu L; Devecioglu O; Anak S; Karakas Z; Yalman N; Biner B; Eryilmaz E; Goksan B; Unuvar A; Agirbasli H; Can M; Bilgen H; Gedikoglu G
    J Chemother; 2001 Jun; 13(3):281-7. PubMed ID: 11450887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective study of cefepime versus ticarcilline/clavulanate as empirical treatment of febrile neutropenia in lymphoma patients.
    Naseem A; Hussain Y; Ahmad B; Aziz MT; Ahmad M; Hameed H
    J Pak Med Assoc; 2011 Jan; 61(1):18-22. PubMed ID: 22368896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of cefepime and ceftazidime in combination with amikacin in the empirical treatment of high-risk patients with febrile neutropenia: a prospective, randomized, multicenter study.
    Erman M; Akova M; Akan H; Korten V; Ferhanoğlu B; Köksal I; Cetinkaya Y; Uzun O; Unal S;
    Scand J Infect Dis; 2001; 33(11):827-31. PubMed ID: 11760163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Imipenem/cilastatin versus ceftazidime-amikacin in the treatment of febrile neutropenic patients].
    Pérez C; Sirham M; Labarca J; Grebe G; Lira P; Oliva J; Duhalde M; Ocqueteau M; Acuña G
    Rev Med Chil; 1995 Mar; 123(3):312-20. PubMed ID: 8525170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized study of cefepime versus ceftazidime plus amikacin in patients with solid tumors treated with high dose chemotherapy (HDC) and peripheral blood stem cell support (PBSCS) with febrile neutropenia.
    Jimeno A; Arcediano A; Bazares S; Amador ML; González-Cortijo L; Ciruelos E; Robles L; Castellano D; Paz-Ares L; Lumbreras C; Hornedo J; Cortés-Funes H
    Clin Transl Oncol; 2006 Dec; 8(12):889-95. PubMed ID: 17169762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.